The blood beryllium lymphocyte proliferation test is used in medical surveillance to identify both beryllium sensitization and chronic beryllium disease. Approximately 50% of individuals with beryllium sensitization have chronic beryllium disease at the time of their initial clinical evaluation, however, the rate of progression from beryllium sensitization to chronic beryllium disease is unknown. We followed a cohort of beryllium-sensitized patients at two-year intervals using bronchoalveolar lavage and repeated transbronchial lung biopsies to determine progression to chronic beryllium disease as evidenced by granulomatous inflammation in lung tissue. Fiftyfive individuals with beryllium sensitization were followed with a range of 2 to 5 clinical evaluations. Disease developed in 17 (31%) of sensitized individuals within an average followup period of 3.8 years (range: 1.0-9.5 years). Thirty-eight of the 55 (69%) remained berylliumsensitized without disease after an average follow-up time of 4.8 years (range: 1.7 -11.6 years).
INTRODUCTION
In the late 1980s and 1990s, several population-based studies of beryllium-exposed workers in the beryllium ceramics and nuclear weapons industries resulted in the resurrected use of a blood test designed to detect beryllium-specific T-cell proliferative responses in the blood of berylliumexposed workers (1) (2) (3) (4) (5) (6) (7) (8) (9) . This test, referred to as the beryllium lymphocyte proliferation test (BeLPT), has been shown to have greater sensitivity and specificity than previously used medical surveillance tools to detect beryllium sensitization (BeS) and chronic beryllium disease (CBD).
The test has been shown to outperform chest radiograph, simple spirometry, and clinical examination in the detection of both BeS and CBD ( 4, 6, 8 ) . The blood BeLPT is now the standard of care in workplace screening and surveillance efforts 3-5, 7, 9, 10 ) . Within these mainly cross-sectional studies, the rate of CBD among those with BeS varied from 14% to 100%. In a report of beryllium ceramic workers by Kreiss et al ( 4 ) , 100% of workers with abnormal blood BeLPTs had CBD on clinical evaluation, some of whom were clinically symptomatic. Beryllium was used historically in that plant, with its use ending 15 years before the surveillance project was initiated. The mean time from first exposure to screening among the study participants was 24 years. In contrast,
Henneberger et al ( 10 ) identified only one employee with CBD among seven short-term workers 4 (14.3%) of a beryllium ceramics facility. In that cohort, the median time from first beryllium exposure to time of blood screening was only one year (range 0.25 -12.75 years). The authors speculated that a certain lung burden of beryllium may be necessary to result in CBD or that BeS progresses to disease with the passage of time, regardless of lung burden or continued exposure.
Longitudinal follow-up of their cohort will be of interest to determine whether those with BeS without disease progress to CBD as the latency period from first exposure increases. As a result, when conducting blood testing for beryllium-exposed workers, it is not always possible to know whether individuals with abnormal BeLPT results have BeS alone or already have CBD.
The merits of the blood BeLPT as a biomarker of beryllium health effect hinge, in part, on whether the blood test detects a clinically-significant abnormality or not. The blood BeLPT has proven utility for those patients with clinical evidence of lung disease by lending specificity to their diagnosis. However, counseling of individuals with abnormal blood BeLPTs, in whom disease signs and symptoms are not obvious, would be greatly enhanced by knowing the rate at which those who do not have CBD at the time of initial evaluation develop disease. We have previously demonstrated that BeS precedes CBD
, but the natural history and rate of progression from sensitization to disease is not fully known ( 12 ) because the literature to date has focused on cross-sectional, and not longitudinal, study designs.
We hypothesize that most beryllium-sensitized workers will eventually develop CBD evidenced by noncaseating granulomas and/or mononuclear cell infiltrates in lung tissue. To test this hypothesis, we performed a longitudinal cohort study of a group of individuals detected through 5 workplace medical surveillance programs as having BeS with no initial evidence of CBD. We have studied these individuals at two-year intervals for evidence of disease progression as evidenced by the new development of granulomatous inflammation detected with lung biopsy.
Some of the results of this study have been previously reported in the form of an abstract ( 13 ) .
METHODS
We conducted a longitudinal cohort study of individuals who were clinically evaluated at 
RESULTS

Study participants
Of all individuals who were referred to National Jewish between those who participated in follow-up with bronchoscopy compared to those who did not.
Non-participants had a higher A-a gradient at rest (11.8 mmHg) compared to participants (9.0 mmHg, p = 0.05). However, we saw no differences in any other measures of exercise physiology.
Progression curve, we estimate that BeS progresses to CBD at a rate between 3.2% -9.2% per year.
Risk factors for progression Table 1 summarizes the demographic and exposure factors for individuals with BeS who progressed to CBD compared to those with BeS who remain free of granulomatous lung disease.
We observed no statistically significant difference in age, gender, race or ethnicity at time of initial evaluation between those who progressed and those who remained sensitized. There were no differences in smoking status at the time of initial diagnosis, with 29.4% of those who progressed being current smokers, compared to 23.7 % of those who remained sensitized.
Smoking status also had no association with progression to CBD as determined on last clinical evaluation. There was a reduction in smoking rates among both the progressors and the non- exposure. There were also no differences with regard to their employment in the nuclear weapons industry. Those who progressed were no more likely to have current beryllium exposure at time of their CBD diagnosis then those who remained sensitized. Of those who were no longer exposed, there were no differences between the two groups in average years since last exposure to diagnostic or most recent follow-up evaluation.
Baseline clinical evaluation Table 2 compares the baseline clinical evaluation results for progressors and nonprogressors.
There were no differences in baseline chest x-ray, pulmonary function and exercise tolerance test We constructed a multiple logistic regression model including exposure and physiologic variable from Tables 1 and 2 . Using a step-down modeling approach and retaining those variable with a significance of 0.10 or less, three variables entered the model (see Table 2E These individuals showed a 6.6% average interval increase in percent lymphocytes in BAL fluid.
One individual was placed on oral corticosteroids by the treating physician two years after CBD diagnosis due to increasing fatigue, dyspnea, and cough, a decrease in exercise work load, and a 33% drop in DL CO percent predicted.
DISCUSSION
This longitudinal clinical follow-up study demonstrates that BeS progresses to CBD over time at a rate of approximately 6% to 8% per year after initial diagnosis. We found that 31% of 55 individuals with BeS who had no evidence of CBD on initial lung biopsy developed CBD on subsequent clinical evaluation. However, continuing follow-up will be needed to determine if all individuals with BeS will eventually develop CBD. Within this study, only lavage lymphocytosis at the time of baseline evaluation and being a beryllium machinist were identified as significant risk factors for progression from BeS to CBD.
Previous evidence of progression from BeS to CBD was presented in a study by Kreiss et al
who identified 6 cases of BeS without CBD among nuclear weapons workers. Three of the six progressed to CBD over a two-year time period. These six individuals are included in the cohort of individuals followed in our study. In addition to the three individuals whose progression was described, one additional individual was found to have progressed to CBD on his fourth followup evaluation, 9.5 years after initial BeS diagnosis, which increases the rate of progression within this small group to 67%. Recently, Barna et al ( 18 ) identified 57 individuals with repeatedly abnormal blood BeLPTs, 24 of whom had granulomatous inflammation on biopsy. Among those without granulomas 5/33 (16%) had abnormal BAL LPT results. The authors reported that over a five-year follow-up period, two of these five individuals developed granulomas, increasing the CBD rate among those sensitized to 46%. Additional longitudinal follow-up of the remaining sensitized individuals, including those without abnormal BAL BeLPTs, will be important to determine how many of the original cohort will eventually progress to disease.
In our study most of the diagnostic pathology came from the pulmonary interstitium, however, five individuals had granuloma formation within bronchial walls. Past pathology studies have described bronchial involvement in CBD ( 19, 20 ) . Bronchial involvement is consistent with the obstructive changes seen in clinical beryllium disease as described by Pappas et al ( 21 ) . Among their patients with clinically evident disease, airflow limitation was the most common spirometric abnormality. Thus, although generally thought of as an "interstitial lung disorder," CBD more accurately should be classified as a "diffuse lung disease," like sarcoidosis, and emphasizes the importance of obtaining both transbronchial and endobronchial biopsy specimens.
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One potential limitation in this study is the possibility of transbronchial biopsy sampling error.
Individuals who may have had normal pathology on first evaluation and who then developed abnormal pathology on subsequent evaluation may have been missed on initial evaluation due to sampling error. The physicians participating in this study consistently obtained from 9 -12 biopsies in an effort to minimize such sampling error. In sarcoidosis, it has been determined that 10 biopsies were adequate to diagnose Stage 1 sarcoidosis, which is the stage most consistent with the early CBD seen in the patients in our study ( 22 ) . Nonetheless, it is possible that if some of our CBD cases had been immediately rebiopsied, CBD might have been detected at the time of first evaluation instead of two to nine years later.
Of the 55 individuals in our study, three individuals had both abnormal BAL BeLPT results and .
Unfortunately, this study was limited by the lack of personal exposure monitoring data for the majority of individuals, leaving us without a measure of quantitative beryllium exposure. Thus, we do not know if individuals with more exposure will progress from BeS to CBD at a faster rate than those with lower or intermittent exposure. Most individuals in this study were exposed in the nuclear weapons industry in a time period for which we have limited access to quantitative exposure estimates. Indirectly, the observation that machinists were more likely to progress from
BeS to CBD suggests that characteristics of exposure contribute to disease risk and progression to CBD. We do know that exposures within the nuclear weapons industry were variable, including people with both active and bystander exposures. Other industries are also represented, including the ceramics industry (3.6%) and the metal machining industry (5.5%) in which we know that the exposures were probably higher and more consistent for machinists than for other employees ( 
5, 24
)
. It is noteworthy that two of our progressors only had incidental or bystander exposure. One individuals was a secretary who worked in a building in which beryllium was used. The other was a security guard who passed through beryllium-using buildings.
Quantitative exposure measures are desirable in any occupational study and lack of precise exposure information makes it difficult for us to predict progression of BeS to CBD based on exposure level. Based on the work history information we were able to collect, we conclude that although workers with possibly higher or more consistent exposures may be more likely to progress to disease (i.e. machinists), individuals with bystander exposure are also at risk of progression.
Because all participants were identified with BeS through workforce medical surveillance, we do not know precisely how long individuals had already been sensitized before undergoing their first clinical evaluation for CBD. This limits our ability to predict the course of progression from the time of first sensitization. However, when a physician evaluates a patient with newly diagnosed BeS, they often do not know how long the worker has been sensitized and need some basis for estimating the likelihood that CBD will or will not develop in the future. Our study provides this information. It is possible that the rate of progression might vary if cases could be tested for disease promptly after BeS first occurs. We know from a previous study in a machining workforce that individuals can develop sensitization within weeks of first exposure or many years after first exposure ( 9 ) . In our study, there is only one individual for whom we know We conducted a longitudinal cohort study of beryllium-exposed workers who were found to have
BeS defined as repeatedly abnormal BeLPT test results. Upon detection of abnormal blood
BeLPTs on two or more occasions, patients were referred for full clinical evaluation to determine if they have BeS or CBD, as detailed below. We enrolled all individuals who were clinically evaluated between 1988 and 1998 and found who have BeS without evidence of CBD.
Longitudinal evaluation was offered every two years after the initial assessment through 2002.
Clinical evaluation was offered sooner if the patients developed symptoms within the interval.
The study was reviewed and approved by the National Jewish Medical and Research Center
Institutional Review Board and all individuals participated in informed consent.
Definitions of BeS and CBD
We defined beryllium sensitization (BeS) as evidence of beryllium specific immune response demonstrated by repeatedly abnormal blood BeLPTs (two of more abnormal tests) with no evidence of granulomas and/or mononuclear cell infiltrates on transbronchial lung biopsy.
Chronic beryllium disease (CBD) was defined as evidence of beryllium sensitization with granulomas and/or mononuclear cell infiltrates in lung tissue (E1).
Blood Beryllium Lymphocyte Proliferation Test (BeLPT)
All initial blood BeLPT tests were performed as part of a beryllium medical surveillance program. The BeLPT was performed within 24 hours of venipuncture using methods previously published (E2). Briefly, mononuclear cells were isolated from heparinized venous blood. They were placed in culture in the presence and absence of beryllium sulfate, across a three-log range of salt concentrations. We verified cell viability and reactivity using the mitogen phytohemagglutinin and antigen tetanus toxoid at optimal concentrations. Cell proliferation was measured by the incorporation of tritiated thymidine into dividing cells after 4 and 6 days in culture. The cells were harvested and the amount of radiolabel that had entered the cells was 
